Identification of mutations in Colombian patients affected with Fabry disease

Fabry Disease (FD) is an X-linked inborn error of glycosphingolipid catabolism, caused by a deficiency of the lisosomal ?-galactosidase A (AGAL). The disorder leads to a vascular disease secondary to the involvement of kidney, heart and the central nervous system. The mutation analysis is a valuable...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2015
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/24132
Acceso en línea:
https://doi.org/10.1016/j.gene.2015.08.018
https://repository.urosario.edu.co/handle/10336/24132
Palabra clave:
Alpha galactosidase
Alpha galactosidase
Adult
Article
Clinical article
Colombian
Exon
Fabry disease
Female
Gene
Gene identification
Gene mutation
Genetic analysis
Genetic counseling
Genotype
Heterozygote
Human
Male
Middle aged
Open reading frame
Phenotype
Priority journal
Sequence analysis
Colombia
Dna mutational analysis
Fabry disease
Genetic association study
Genetic heterogeneity
Genetics
Heterozygote detection
Molecular genetics
Mutation
Nucleotide sequence
Adult
Alpha-galactosidase
Base sequence
Colombia
Dna mutational analysis
Fabry disease
Female
Genetic association studies
Genetic heterogeneity
Heterozygote detection
Humans
Male
Middle aged
Molecular sequence data
Mutation
Gla gene
Lysosomal disorder
Mutations
?-galactosidase a
Rights
License
Abierto (Texto Completo)
Description
Summary:Fabry Disease (FD) is an X-linked inborn error of glycosphingolipid catabolism, caused by a deficiency of the lisosomal ?-galactosidase A (AGAL). The disorder leads to a vascular disease secondary to the involvement of kidney, heart and the central nervous system. The mutation analysis is a valuable tool for diagnosis and genetic counseling. Although more than 600 mutations have been identified, most mutations are private. Our objective was to describe the analysis of nine Colombian patients with Fabry disease by automated sequencing of the seven exons of the GLA gene. Two novel mutations were identified in two patients affected with the classical subtype of FD, in addition to other 6 mutations previously reported. The present study confirms the heterogeneity of mutations in Fabry disease and the importance of molecular analysis for genetic counseling, female heterozygotes detection as well as therapeutic decisions. © 2015 Elsevier B.V.